F-18 FDG PET/CT在胰臟癌的臨床應用

10.6666/ClinMed.202403_93(3).0024

王昱豐；李哲皓；彭南靖

胰臟癌（pancreatic cancer） ； 正子斷層掃描／電腦斷層掃描（positron emission tomography/computed tomography, PET/CT） ； 放射性氟化去氧葡萄（2-deoxy-2-[F-18] fluoroglucose, F-18 FDG）

臨床醫學月刊

93卷3期（2024 / 03 / 29）

133 - 140

繁體中文

胰臟癌是所有惡性腫瘤中預後甚差的癌症之一，其年發病率與死亡率相當接近。在胰臟癌患者的治療與預後評估中，早期診斷和正確分期相當重要；在這方面，影像檢查在腫瘤檢測、分期和術前評估方面相當重要，並可以為胰臟癌的診斷和治療提供可靠的依據。正子斷層掃描／電腦斷層掃描（PET／CT）是由PET和CT組成的影像設備，放射性氟化去氧葡萄糖（F-18 FDG）則是目前臨床上常用的正子製劑。由於癌細胞比其他普通細胞更能攝取葡萄糖，而F-18 FDG與葡萄糖的結構相似。因此，在注射F-18 FDG後，PET／CT可以準確偵測出胰臟腫瘤細胞的代謝能力和解剖位置，從而可以對患者的整體狀況作出完整的評估，對於早期診斷和準確分期、預測存活率、評估治療效果和監測胰臟癌復發方面有著相當重要的關鍵。本文回顧與討論F-18 FDG PET／CT在胰臟癌中的臨床應用。

1. Kamisawa T, Wood LD, Itoi T, et al. Pancreatic cancer. The Lancet 2016;388:73-85.
   連結：
2. Pu Y, Wang C, Zhao S, et al.The clinical application of(18)F-FDG PET/CT in pancreatic cancer: a narrative review. Transl Cancer Res 2021;10:3560-75.
   連結：
3. Howard BA, Wong TZ. 18F-FDG-PET/CT Imaging for Gastrointestinal Malignancies. Radiol Clin North Am 2021;59:737-53.
   連結：
4. Dibble EH, Karantanis D, Mercier G, et al. PET/CT of cancer patients: part 1, pancreatic neoplasms. American journal of roentgenology 2012;199:952-67.
   連結：
5. Kikuyama M, Kamisawa T, Kuruma S, et al. Early Diagnosis to Improve the Poor Prognosis of Pancreatic Cancer. Cancers(Basel). 2018;10.
   連結：
6. Reske SN, Grillenberger KG, Glatting G, et al. Overexpression of glucose transporter 1 and increased FDG uptake in pancreatic carcinoma. J Nucl Med 1997;38:1344-8.
   連結：
7. Jha P, Bijan B. PET/CT for Pancreatic Malignancy: Potential and Pitfalls. J Nucl Med Technol 2015;43:92-7.
   連結：
8. Pakzad F, Groves AM, Ell PJ. The role of positron emission tomography in the management of pancreatic cancer. Semin Nucl Med 2006;36:248-56.
   連結：
9. Toft J, Hadden WJ, Laurence JM, et al. Imaging modalities in the diagnosis of pancreatic adenocarcinoma: A systematic review and meta-analysis of sensitivity, specificity and diagnostic accuracy. Eur J Radiol 2017;92:17-23.
   連結：
10. Ergul N, Gundogan C, Tozlu M, et al.Role of(18)F-fluorodeoxyglucose positron emission tomography/computed tomography in diagnosis and management of pancreatic cancer; comparison with multidetector row computed tomography, magnetic resonance imaging and endoscopic ultrasonography. Rev Esp Med Nucl Imagen Mol 2014;33:159-64.
    連結：
11. Sur YK, Kim YC, Kim JK, et al. Comparison of Ultrasound-Guided Core Needle Biopsy and Endoscopic Ultrasound-Guided Fine-Needle Aspiration for Solid Pancreatic Lesions. J Ultrasound Med 2015;34:2163-9.
    連結：
12. Lin JL, Barthel JS, Keshishian J, et al. Negative predictive value of positron emission tomography/computed tomography in patients with a clinical suspicion of pancreatic cancer. Pancreas 2011;40:653-6.
    連結：
13. Ghaneh P, Hanson R, Titman A, et al.PET-PANC: multicentre prospective diagnostic accuracy and health economic analysis study of the impact of combined modality 18fluorine-2-fluoro-2-deoxy-d-glucose positron emission tomography with computed tomography scanning in the diagnosis and management of pancreatic cancer. Health Technol Assess 2018;22:1-114.
    連結：
14. Zhang J, Zuo CJ, Jia NY, et al.Cross-modality PET/CT and contrast-enhanced CT imaging for pancreatic cancer. World J Gastroenterol. 2015;21:2988-96.
    連結：
15. Soriano A, Castells A, Ayuso C, et al. Preoperative staging and tumor resectability assessment of pancreatic cancer: prospective study comparing endoscopic ultrasonography, helical computed tomography, magnetic resonance imaging, and angiography. Am J Gastroenterol 2004;99:492-501.
    連結：
16. Sahani DV, Bonaffini PA, Catalano OA, et al.State-of-the-art PET/CT of the pancreas: current role and emerging indications. Radiographics 2012;32:1133-58; discussion 58-60.
    連結：
17. Heinrich S, Goerres GW, Schäfer M, et al.Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness. Ann Surg 2005;242:235-43.
    連結：
18. Farma JM, Santillan AA, Melis M, et al. PET/CT fusion scan enhances CT staging in patients with pancreatic neoplasms. Ann Surg Oncol 2008;15:2465-71.
    連結：
19. Wang L, Dong P, Wang WG, et al.Positron emission tomography modalities prevent futile radical resection of pancreatic cancer: A meta-analysis. Int J Surg 2017;46:119-25.
    連結：
20. Kauhanen SP, Komar G, Seppänen MP, et al. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer. Ann Surg 2009;250:957-63.
    連結：
21. Yoneyama T, Tateishi U, Endo I, et al. Staging accuracy of pancreatic cancer: comparison between non-contrast-enhanced and contrast-enhanced PET/CT. Eur J Radiol 2014;83:1734-9.
    連結：
22. Wang S, Shi H, Yang F, et al.The value of(18)F-FDG PET/CT and carbohydrate antigen 19-9 in predicting lymph node micrometastases of pancreatic cancer. Abdom Radiol(NY)2019;44:4057-62.
    連結：
23. Wang Z, Chen JQ, Liu JL, et al.FDG-PET in diagnosis, staging and prognosis of pancreatic carcinoma: a meta-analysis. World J Gastroenterol 2013;19:4808-17.
    連結：
24. Sidaway P. Pancreatic cancer: TCGA data reveal a highly heterogeneous disease. Nat Rev Clin Oncol 2017;14:648.
    連結：
25. Fahrmann JF, Bantis LE, Capello M, et al.A Plasma-Derived Protein-Metabolite Multiplexed Panel for Early-Stage Pancreatic Cancer. J Natl Cancer Inst 2019;111:372-9.
    連結：
26. Luo G, Liu C, Guo M, et al. Potential Biomarkers in Lewis Negative Patients With Pancreatic Cancer. Ann Surg. 2017;265:800-5.
    連結：
27. Hyun SH, Kim HS, Choi SH, et al. Intratumoral heterogeneity of(18)F-FDG uptake predicts survival in patients with pancreatic ductal adenocarcinoma. Eur J Nucl Med Mol Imaging 2016;43:1461-8.
    連結：
28. Kim YI, Kim YJ, Paeng JC, et al. Heterogeneity index evaluated by slope of linear regression on(18)F-FDG PET/CT as a prognostic marker for predicting tumor recurrence in pancreatic ductal adenocarcinoma. Eur J Nucl Med Mol Imaging 2017;44:1995-2003.
    連結：
29. Okamoto K, Koyama I, Miyazawa M, et al. Preoperative 18 [F]-fluorodeoxyglucose positron emission tomography/computed tomography predicts early recurrence after pancreatic cancer resection. Int J Clin Oncol 2011;16:39-44.
    連結：
30. Schellenberg D, Quon A, Minn AY, et al. 18Fluorodeoxyglucose PET is prognostic of progression-free and overall survival in locally advanced pancreas cancer treated with stereotactic radiotherapy. Int J Radiat Oncol Biol Phys 2010;77:1420-5.
    連結：
31. Zhang A, Ren S, Yuan Y, et al. Prognostic values of 18F-FDG PET/CT metabolic parameters and clinical figures in locally advanced pancreatic cancer underwent chemotherapy combined with stereotactic body radiation therapy. Medicine(Baltimore)2019;98:e15064.
    連結：
32. Choi HJ, Lee JW, Kang B, et al. Prognostic significance of volume-based FDG PET/CT parameters in patients with locally advanced pancreatic cancer treated with chemoradiation therapy. Yonsei Med J 2014;55:1498-506.
    連結：
33. Javadi S, Karbasian N, Bhosale P, et al. Imaging findings of recurrent pancreatic cancer following resection. Abdom Radiol(NY)2018;43:489-96.
    連結：
34. Jung W, Jang JY, Kang MJ, et al. The clinical usefulness of 18F-fluorodeoxyglucose positron emission tomography-computed tomography(PET-CT)in follow-up of curatively resected pancreatic cancer patients. HPB(Oxford)2016;18:57-64.
    連結：
35. Kitajima K, Murakami K, Yamasaki E, et al. Performance of integrated FDG-PET/contrast-enhanced CT in the diagnosis of recurrent pancreatic cancer: comparison with integrated FDG-PET/non-contrast-enhanced CT and enhanced CT. Mol Imaging Biol 2010;12:452-9.
    連結：
36. Rayamajhi S, Balachandran A, Katz M, et al. Utility of(18)F-FDG PET/CT and CECT in conjunction with serum CA 19-9 for detecting recurrent pancreatic adenocarcinoma. Abdom Radiol(NY)2018;43:505-13.
    連結：
37. Albano D, Familiari D, Gentile R, et al. Clinical and prognostic value of 18F-FDG-PET/CT in restaging of pancreatic cancer. Nucl Med Commun 2018;39:741-6.
    連結：
38. Barreto SG, Loveday B, Windsor JA, et al. Detecting tumour response and predicting resectability after neoadjuvant therapy for borderline resectable and locally advanced pancreatic cancer. ANZ J Surg 2019;89:481-7.
    連結：
39. Abdelrahman AM, Goenka AH, Alva-Ruiz R, et al. FDG-PET Predicts Neoadjuvant Therapy Response and Survival in Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma. J Natl Compr Canc Netw 2022;20:1023-32.e3.
    連結：
40. Low G, Panu A, Millo N, et al. Multimodality imaging of neoplastic and nonneoplastic solid lesions of the pancreas. Radiographics 2011;31:993-1015.
    連結：
41. Pery C, Meurette G, Ansquer C, et al. Role and limitations of 18F-FDG positron emission tomography(PET)in the management of patients with pancreatic lesions. Gastroenterologie clinique et biologique 2010;34:465-74.
    連結：
42. van Kouwen MC, Jansen JB, van Goor H, et al. FDG-PET is able to detect pancreatic carcinoma in chronic pancreatitis. Eur J Nucl Med Mol Imaging 2005;32:399-404.
    連結：
43. Society. AC. Cancer facts & figures 2023: American Cancer Society; 2023
44. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020;70:7-30.
45. Sun Y, Duan Q, Wang S, et al.Diagnosis of pancreatic cancer using ¹⁸F-FDG PET/CT and CA19-9 with SUVmax association to clinical characteristics. J buon 2015;20:452-9.